High-Dose Atorvastatin after Stroke or Transient Ischemic Attack
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Statins reduce the incidence of strokes among patients at increased risk for cardiovascular disease; whether they reduce the risk of stroke after a recent stroke or transient ischemic attack (TIA) remains to be established. METHODS: We randomly assigned 4731 patients who had had a stroke or TIA within one to six months before study entry, had low-density lipoprotein (LDL) cholesterol levels of 100 to 190 mg per deciliter (2.6 to 4.9 mmol per liter), and had no known coronary heart disease to double-blind treatment with 80 mg of atorvastatin per day or placebo. The primary end point was a first nonfatal or fatal stroke. RESULTS: The mean LDL cholesterol level during the trial was 73 mg per deciliter (1.9 mmol per liter) among patients receiving atorvastatin and 129 mg per deciliter (3.3 mmol per liter) among patients receiving placebo. During a median follow-up of 4.9 years, 265 patients (11.2 percent) receiving atorvastatin and 311 patients (13.1 percent) receiving placebo had a fatal or nonfatal stroke (5-year absolute reduction in risk, 2.2 percent; adjusted hazard ratio, 0.84; 95 percent confidence interval, 0.71 to 0.99; P=0.03; unadjusted P=0.05). The atorvastatin group had 218 ischemic strokes and 55 hemorrhagic strokes, whereas the placebo group had 274 ischemic strokes and 33 hemorrhagic strokes. The five-year absolute reduction in the risk of major cardiovascular events was 3.5 percent (hazard ratio, 0.80; 95 percent confidence interval, 0.69 to 0.92; P=0.002). The overall mortality rate was similar, with 216 deaths in the atorvastatin group and 211 deaths in the placebo group (P=0.98), as were the rates of serious adverse events. Elevated liver enzyme values were more common in patients taking atorvastatin. CONCLUSIONS: In patients with recent stroke or TIA and without known coronary heart disease, 80 mg of atorvastatin per day reduced the overall incidence of strokes and of cardiovascular events, despite a small increase in the incidence of hemorrhagic stroke. (ClinicalTrials.gov number, NCT00147602 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the recently published Lipitor's Effect in Alzheimer's Dementia (LEADe) trial, which included 640 randomized patients with mild Alzheimer disease, intensive lipid lowering by the addition of atorvastatin (80 mg) to donepezil did not improve cognitive function over a 72-week period.464”
In the citing paper
“Data from RCTs and meta-analyses indicate that routine early use of high-intensity statin therapy is associated with rapid and sustained clinical benefits [438-442].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [438]
In the citing paper
“Following stroke or TIA, 34 patients are at risk not only of recurrent cerebrovascular events but also of other major CV events including MI.”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [34]
In the citing paper
“Secondary prevention therapy with statins reduces the risk of recurrent stroke (by 12%), MI and vascular death.422,428”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [428]
In the citing paper
“Many reports have also indicated that there is no clear relationship between the TG level and cerebrovascular disease856, 862, 863).”
From Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017 (2018) · cites this paper as [862]
Citations
Cites
Expert Panel on Detection, E. (2001) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.285.19.2486 · Cited by 26,011
(1998) · New England Journal of Medicine · doi:10.1056/nejm199811053391902 · Cited by 5,261
Sever, P. S., Dahlöf, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12948-0 · Cited by 3,782
Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755
Cerebral Vascular Accidents in Patients over the Age of 60: II. Prognosis
Rankin, J. (1957) · Scottish Medical Journal · doi:10.1177/003693305700200504 · Cited by 2,506
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Iso, H., Jacobs, D. R., Wentworth, D., Neaton, J. D., Cohen, J. D., & for the MRFIT Research Group* (1989) · New England Journal of Medicine · doi:10.1056/nejm198904063201405 · Cited by 1,133
Amarenco, P., Labreuche, J., Lavallée, P., & Touboul, P.-J. (2004) · Stroke · doi:10.1161/01.str.0000147965.52712.fa · Cited by 746
Research works printed but not linked: 1
- Waters DD, 2005, Circulation, 112, 2020
Cited by
Items 701–800 of 1,005
The benefit of statins in non-cardiac vascular surgery patients
Stalenhoef, A. F. H. (2009) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2008.11.070 · Cited by 40
Review: Stroke in type 2 diabetes
Sander, D., Sander, K., & Poppert, H. (2008) · The British Journal of Diabetes · doi:10.1177/1474651408096677 · Cited by 41
Chen, P.-S., Cheng, C., Yang, Y. K., & Li, Y. (2016) · Circulation Journal · doi:10.1253/circj.cj-15-0753 · Cited by 41
Ganz, P., Amarenco, P., Goldstein, L. B., Sillesen, H. H., Bao, W., Preston, G. M., & Welch, K. M. A. (2017) · Stroke · doi:10.1161/strokeaha.117.017965 · Cited by 40
Total cholesterol and stroke mortality in middle-aged and elderly adults: A prospective cohort study
Yi, S., Shin, D., Kim, H., Yi, J., & Ohrr, H. (2017) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2017.12.003 · Cited by 42
O'Donnell, M. J., McQueen, M., Sniderman, A. D., Paré, G., Wang, X., Hankey, G. J., Rangarajan, S., Chin, S. L., Ps, R., Ferguson, J. P., et al. (2022) · Journal of Stroke · doi:10.5853/jos.2021.02152 · Cited by 45
Aeschbacher‐Germann, M., Kaiser, N., Speierer, A., Blum, M. R., Bauer, D. C., Giovane, C. D., Aujesky, D., Gencer, B., Rodondi, N., & Moutzouri, E. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.026551 · Cited by 46
Paciaroni, M., Agnelli, G., Ageno, W., Caso, V., Corea, F., Lanari, A., Alberti, A., Previdi, P., Fedele, M., Manina, G., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.016 · Cited by 38
Yin, Y., Zhang, L., Marshall, I. J., Wolfe, C. D. A., & Wang, Y. (2022) · Neuroepidemiology · doi:10.1159/000525672 · Cited by 43
Treatment of Ischemic Stroke by Atorvastatin-Loaded PEGylated Liposome
Thomas, R. G., Kim, J., Kim, J., Yoon, J., Choi, K., & Jeong, Y. (2023) · Translational Stroke Research · doi:10.1007/s12975-023-01125-9 · Cited by 37
Statin Use and the Risk of Incident Diabetes Mellitus: A Review of the Literature
Colbert, J. D., & Stone, J. A. (2012) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2012.03.021 · Cited by 39
Role of HMG-CoA Reductase Inhibitors in Neurological Disorders: Progress to Date
Reiss, A. B., & Wirkowski, E. J. (2007) · Drugs · doi:10.2165/00003495-200767150-00001 · Cited by 44
Fuentes, B., Gállego, J., Gil-Núñez, A., Morales, A., Purroy, F. F., Roquer, J., Segura, T., Tejada, J., Lago, A. P., Díez‐Tejedor, E., et al. (2011) · Neurología · doi:10.1016/j.nrl.2011.06.002 · Cited by 56
Mancia, G., Dominiczak, A. F., Fagard, R. H., Heagerty, A. M., Kjeldsen, S. E., Laurent, S., Schmieder, R. E., Vahanian, A. S., Camm, A. J., Dean, V., et al. (2007) · Cited by 50
Statin Pretreatment and Microembolic Signals in Large Artery Atherosclerosis
Safouris, A., Krogias, C., Sharma, V. K., Katsanos, A. H., Faissner, S., Roussopoulou, A., Zompola, C., Kneiphof, J., Kargiotis, O., Deftereos, S. G., et al. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309292 · Cited by 37
The Association of Statin Therapy with Incident Diabetes: Evidence, Mechanisms, and Recommendations
Agarwala, A., Kulkarni, S., & Maddox, T. M. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0995-6 · Cited by 42
Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania
Regenhardt, R. W., Biseko, M. R., Shayo, A. F., Mmbando, T. N., Grundy, S. J., Xu, A., Saadi, A., Wibecan, L., Kharal, G. A., Parker, R. A., et al. (2018) · International Journal for Quality in Health Care · doi:10.1093/intqhc/mzy188 · Cited by 38
“3 Atorvastatin in 6 months, 5 years recurrent stroke 95 83 [40] SPARCL [16] 13−11 = 2 52.”
BackgroundInfluentialUse of Statins After Ischemic Stroke in Young Adults and Its Association With Long-Term Outcome
van Dongen, M. M. E., Aarnio, K., Martinez‐Majander, N., Pirinen, J., Sinisalo, J. P., Lehto, M., Kaste, M., Tatlisumak, T., de Leeuw, F., & Jukka Putaala, A. (2019) · Stroke · doi:10.1161/strokeaha.119.026992 · Cited by 38
Yeo, S., Toh, M. P. H. S., Lee, S. H., Seet, R. C. S., Wong, L. Y., & Yau, W. (2020) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4981 · Cited by 50
“The observation that the aHRs for the composite outcomes were comparatively lower than stroke recurrence was similar to previous research, which reported that though the use of antiplatelets or statins reduced recurrent stroke, their effects on mortality in ischemic stroke patients were lower.(9,49-51) The use of mort…”
BackgroundResultAppelros, P., & Åsberg, S. (2020) · Handbook of clinical neurology · doi:10.1016/b978-0-444-64123-6.00021-7 · Cited by 45
Kent, D. M., Leung, L. Y., Zhou, Y., Luetmer, P. H., Kallmes, D. F., Nelson, J., Fu, S., Zheng, C., Liu, H., & Chen, W. (2021) · Neurology · doi:10.1212/wnl.0000000000012602 · Cited by 37
What Does ‘Best Medical Therapy’ Really Mean?
Sillesen, H. H. (2007) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2007.10.003 · Cited by 38
Transient ischaemic attack: clinical relevance, risk prediction and urgency of secondary prevention
Giles, M. F., & Rothwell, P. M. (2009) · Current Opinion in Neurology · doi:10.1097/wco.0b013e32831f1977 · Cited by 37
Ankolekar, S., Rewell, S. S. J., Howells, D. W., & Bath, P. M. (2012) · International Journal of Stroke · doi:10.1111/j.1747-4949.2012.00802.x · Cited by 44
The paradox of cholesterol and stroke
Amarenco, P., & Steg, P. G. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61751-6 · Cited by 41
Binswanger’s disease: toward a diagnosis agreement and therapeutic approach
Huisa, B. N., & Rosenberg, G. A. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.956726 · Cited by 43
Hou, B., Ma, J., Guo, X., Ju, F., Gao, J., Wang, D., Liu, J., Li, X., Zhang, S., & Ren, H. (2016) · Molecular Neurobiology · doi:10.1007/s12035-016-9740-6 · Cited by 41
Asymptomatic carotid stenosis: what to do
Redgrave, J. N. E., & Rothwell, P. M. (2007) · Current Opinion in Neurology · doi:10.1097/wco.0b013e328012da60 · Cited by 37
Arsenault, B. J., Boekholdt, S. M., Mora, S., DeMicco, D. A., Bao, W., Tardif, J.-C., Amarenco, P., Pedersen, T., Barter, P., & Waters, D. D. (2014) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2014.01.414 · Cited by 36
Effect of Serum Lipid Levels on Stroke Outcome after rt-PA Therapy: SAMURAI rt-PA Registry
Makihara, N., Okada, Y., Koga, M., Shiokawa, Y., Nakagawara, J., Furui, E., Kimura, K., Yamagami, H., Hasegawa, Y., Kario, K., et al. (2012) · Cerebrovascular Diseases · doi:10.1159/000334664 · Cited by 40
Spence, J. D. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.114 · Cited by 41
Statin treatment is associated with improved prognosis in patients with AF-related stroke
Ntaios, G., Papavasileiou, V., Makaritsis, K. P., Milionis, H. J., Manios, E. D., Michel, P., Lip, G. Y. H., & Vemmos, K. N. (2014) · International Journal of Cardiology · doi:10.1016/j.ijcard.2014.09.031 · Cited by 36
“AFwas an exclusion criterion in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial [2].”
MethodCerebral microbleeds: A new dilemma in stroke medicine
Kakar, P., Charidimou, A., & Werring, D. J. (2012) · JRSM Cardiovascular Disease · doi:10.1177/2048004012474754 · Cited by 43
Transient ischemic attack service provision: A review of available service models
Ranta, A. A., & Barber, P. A. (2016) · Neurology · doi:10.1212/wnl.0000000000002339 · Cited by 39
Statins and risk of poststroke hemorrhagic complications
Scheitz, J. F., Macisaac, R. L., Abdul‐Rahim, A. H., Siegerink, B., Bath, P. M., Endres, M., Lees, K. R., Nolte, C. H., Lees, K. R., Bluhmki, E., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000002606 · Cited by 41
Statins for the Primary Prevention of Coronary Heart Disease
Li, M., Wang, X., Li, X., Chen, H., Hu, Y., Zhang, X., Tang, X., Miao, Y., Tian, G., & Shang, H. (2019) · BioMed Research International · doi:10.1155/2019/4870350 · Cited by 43
“The participants in three studies had hypertension [31, 37, 40], in three studies they had dyslipidaemia [28, 36, 38], in three studies they suffered cerebrovascular diseases [25, 34, 39] and in one study they had type 2 diabetes [27].”
BackgroundMethodInfluentialSphingolipidomics Investigation of the Temporal Dynamics after Ischemic Brain Injury
Chao, H., Lee, T.-H., Chiang, C.-S., Yang, S.-Y., Kuo, C., & Tang, S. (2019) · Journal of Proteome Research · doi:10.1021/acs.jproteome.9b00370 · Cited by 36
Barriers and Facilitators to Using Statins: A Qualitative Study With Patients and Family Physicians
Butalia, S., Lee-Krueger, R. C. W., McBrien, K. A., Leung, A. A. C., Anderson, T. J., Quan, H., Naugler, C. T., Chen, G., & Campbell, D. J. T. (2020) · CJC Open · doi:10.1016/j.cjco.2020.07.002 · Cited by 42
CNS and peripheral immunity in cerebral ischemia: partition and interaction
Kim, E., & Cho, S. (2020) · Experimental Neurology · doi:10.1016/j.expneurol.2020.113508 · Cited by 42
Bousser, M., Amarenco, P., Chamorro, Á., Fisher, M., Ford, I., Fox, K., Hennerici, M. G., Mattle, H. P., & Rothwell, P. M. (2009) · Cerebrovascular Diseases · doi:10.1159/000216835 · Cited by 37
Statins in Neurological Disorders: Mechanisms and Therapeutic Value
Reiss, A. B., & Wirkowski, E. J. (2009) · The Scientific World JOURNAL · doi:10.1100/tsw.2009.141 · Cited by 37
Statin use after intracerebral hemorrhage: a 10‐year nationwide cohort study
Tai, S., Lin, F., Lee, C., Chang, C., Wu, M., & Chien, C. (2016) · Brain and Behavior · doi:10.1002/brb3.487 · Cited by 38
Statin use and other factors associated with mortality after major lower extremity amputation
DeCarlo, C. S., Scher, L. A., Shariff, S., Phair, J., Lipsitz, E. C., & Garg, K. (2017) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2017.01.048 · Cited by 39
Australian Clinical Guidelines for Acute Stroke Management 2007
Hill, K. M. (2008) · International Journal of Stroke · doi:10.1111/j.1747-4949.2008.00189.x · Cited by 36
Lipid lowering for prevention of venous thromboembolism: a network meta-analysis
Farmakis, I. T., Christodoulou, K. C., Hobohm, L., Konstantinides, S., & Valerio, L. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae361 · Cited by 36
Wang, T., Xue-bin, C., Zhang, T., Chen, X., Peipei, H., Chen, Z., & Beisha, T. (2015) · International Journal of Neuroscience · doi:10.3109/00207454.2015.1012758 · Cited by 37
Collier, D., Poulter, N. R., Dahlöf, B., Sever, P., Wedel, H., Buch, J., & Caulfield, M. J. (2011) · Journal of Hypertension · doi:10.1097/hjh.0b013e328342c8f7 · Cited by 37
Tang, X., Tu, Q., Cao, H., Zhong, W., & Ding, B. (2014) · Neural Regeneration Research · doi:10.4103/1673-5374.128220 · Cited by 40
Targeting LDL: Is lower better and is it safe?
Stein, E. A., & Raal, F. J. (2013) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2013.10.010 · Cited by 38
Etherton‐Beer, C., Blacker, D., Bynevelt, M., Hankey, G. J., & Puddey, I. B. (2011) · International Journal of Stroke · doi:10.1111/j.1747-4949.2011.00653.x · Cited by 40
Small Vessel Cerebrovascular Disease: The Past, Present, and Future
Behrouz, R., Malek, A. R., & Torbey, M. (2012) · Stroke Research and Treatment · doi:10.1155/2012/839151 · Cited by 40
Kawai, H., Deguchi, S., Deguchi, K., Yamashita, T., Ohta, Y., Shang, J., Tian, F., Zhang, X., Liu, N., Liu, W., et al. (2010) · Brain Research · doi:10.1016/j.brainres.2010.10.046 · Cited by 35
Aspirin for primary prevention of cardiovascular disease
Nansseu, J. R., & Noubiap, J. J. (2015) · Thrombosis Journal · doi:10.1186/s12959-015-0068-7 · Cited by 38
Adherence to statin therapy and the incidence of ischemic stroke in patients with diabetes
Korhonen, M. J., Ruokoniemi, P. T., Ilomäki, J., Meretoja, A., Helin‐Salmivaara, A., & Huupponen, R. (2015) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.3936 · Cited by 39
Cortical modulation of cardiac autonomic activity in ischemic stroke patients
Constantinescu, V. A., Matei, D. V., Cuciureanu, D. I., Corciovă, C., Ignat, B. E., & Popescu, C. D. (2016) · Acta Neurologica Belgica · doi:10.1007/s13760-016-0640-3 · Cited by 35
Harris, S., Kurniawan, M., Rasyid, A., Mesiano, T., & Hidayat, R. (2018) · SAGE Open Medicine · doi:10.1177/2050312118784312 · Cited by 38
Angelidi, A. M., Stambolliu, E., Adamopoulou, K., & Kousoulis, A. A. (2018) · International Journal of Endocrinology · doi:10.1155/2018/8380192 · Cited by 43
The Benefits and Risks of Statin Therapy in Ischemic Stroke: A Review of the Literature
Zhao, S., Wang, Z., & Xiao, Z.-J. (2019) · Neurology India · doi:10.4103/0028-3886.266274 · Cited by 39
Central Nervous System Tissue Regeneration after Intracerebral Hemorrhage: The Next Frontier
Zhang, R., Xue, M., & Yong, V. W. (2021) · Cells · doi:10.3390/cells10102513 · Cited by 40
Buttmann, M., Lorenz, A., Weishaupt, A., & Rieckmann, P. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04563.x · Cited by 35
“Furthermore, preventive statin treatment of humans reduces the incidence of stroke (Endres 2005; Amarenco et al. 2006) although hypercholesterinemia is no major risk factor for stroke (Prospective Studies Collaboration 1995) and statins are effective in stroke prevention also in normocholesterolemic patients (Heart Pr…”
BackgroundDhamoon, M. S., & Elkind, M. S. V. (2010) · Circulation · doi:10.1161/circulationaha.109.921072 · Cited by 36
Risk Factor Management for Stroke Prevention
Prabhakaran, S., & Chong, J. Y. (2014) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/01.con.0000446102.82420.64 · Cited by 48
Kim, D., Lee, S., Kim, B. J., Jung, K., Yu, K., Lee, B., Roh, J., & for Korean Stroke Registry investigators (2013) · European Heart Journal · doi:10.1093/eurheartj/eht185 · Cited by 37
Boulanger, M., Li, L., Lyons, S., Lovett, N. G., Kubiak, M. M., Silver, L. E., Touzé, E., Rothwell, P. M., & Study, O. B. O. T. O. V. (2019) · Stroke · doi:10.1161/strokeaha.119.025831 · Cited by 36
Hodis, H. N. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.suppl_4.s3 · Cited by 36
Kasab, S. A., Nguyen, T. N., Derdeyn, C. P., Yaghi, S. R., Amin‐Hanjani, S., Kicielinski, K., Zaidat, O. O., & de Havenon, A. (2024) · Stroke · doi:10.1161/strokeaha.123.043635 · Cited by 36
Gao, Y., Jiang, L., Pan, Y., Chen, W., Jing, J., Wang, C., Johnston, S. C., Amarenco, P., Bath, P. M., Yang, Y., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2024.1433 · Cited by 40
Shao, S., Xu, M., Zhou, J., Ge, X., Chen, G., Guo, L., Luo, L., Li, K., Zhu, Z., & Zhang, F. (2016) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-016-0412-x · Cited by 34
Huang, B., Zhou, Z.-Y., Li, S., Huang, X.-H., Tang, J., Hoi, M. P. M., & Lee, S. M. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.025 · Cited by 33
Pikija, S., Sztriha, L., Killer‐Oberpfalzer, M., Weymayr, F., Hecker, C., Ramesmayer, C., Hauer, L., & Sellner, J. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1391-3 · Cited by 34
Thrombolytic Therapy for Acute Ischemic Stroke: Past and Future
Shibata, K., Hashimoto, T., Miyazaki, T., Miyazaki, A., & Nobe, K. (2019) · Current Pharmaceutical Design · doi:10.2174/1381612825666190319115018 · Cited by 37
New Horizons in Pharmacologic Therapy for Secondary Stroke Prevention
Katsanos, A. H., & Hart, R. G. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2494 · Cited by 37
Sprügel, M. I., Kuramatsu, J. B., Volbers, B., Saam, J. I., Sembill, J. A., Gerner, S. T., Balk, S., Hamer, H. M., Lücking, H., Hoelter, P., et al. (2021) · Stroke · doi:10.1161/strokeaha.120.029345 · Cited by 37
Low‐density lipoprotein cholesterol and lifespan: A Mendelian randomization study
Daghlas, I., & Gill, D. (2021) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14811 · Cited by 37
Benefits and drawbacks of statins and non-statin lipid lowering agents in carotid artery disease
Paraskevas, K. I., Gloviczki, P., Antignani, P. L., Comerota, A. J., Dardik, A., Davies, A. H., Eckstein, H., Faggioli, G., Fernandes, J. F. E., Fraedrich, G., et al. (2022) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2022.05.003 · Cited by 35
Ribeiro, R. A., Ziegelmann, P. K., Duncan, B. B., Stella, S. F., Vieira, J. L. D. C., Restelatto, L. M. F., Moriguchi, E. H., & Polanczyk, C. A. (2011) · International Journal of Cardiology · doi:10.1016/j.ijcard.2011.10.128 · Cited by 34
“5 1 SPARCL [30] 2006 A80 vs placebo 4731 Patients with prior stroke or TIA but without known CHD 62.”
BackgroundEffects of Statins on Progression of Subclinical Brain Infarct
Fu, J. H., Mok, V., Lam, W. W. M., Wong, A., Chu, C. W., Xiong, Y., Ng, P. W., Tsoi, T. H., Yeung, M. W., & Wong, K. S. (2010) · Cerebrovascular Diseases · doi:10.1159/000313614 · Cited by 35
Mixed Cerebrovascular Disease and the Future of Stroke Prevention
Fisher, M., Vasilevko, V., & Cribbs, D. H. (2012) · Translational Stroke Research · doi:10.1007/s12975-012-0185-6 · Cited by 38
Tang, Z., Li, R., Guo, X., Wang, Z., & Wu, J. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177553 · Cited by 38
Statins and stroke: prevention and beyond
Prinz, V., & Endres, M. (2010) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283424c53 · Cited by 37
Amarenco, P., Callahan, A., Campese, V. M., Goldstein, L. B., Hennerici, M. G., Messig, M., Sillesen, H. H., Welch, K. M. A., Wilson, D. J., & Zivin, J. A. (2014) · Stroke · doi:10.1161/strokeaha.114.005832 · Cited by 36
Yu, S. C. H., Leung, T. W. H., Lee, K. T., & Wong, K. S. (2013) · Journal of NeuroInterventional Surgery · doi:10.1136/neurintsurg-2012-010608 · Cited by 35
Potey, C., Ouk, T., Pétrault, O., Pétrault, M., Bérézowski, V., Salleron, J., Bordet, R., & Gautier, S. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13285 · Cited by 35
Klarin, D. M., Cambria, R. P., Ergul, E. A., Silverman, S. B., Patel, V. I., LaMuraglia, G. M., Conrad, M. F., & Clouse, W. D. (2018) · Journal of Vascular Surgery · doi:10.1016/j.jvs.2018.01.064 · Cited by 33
Medication Adherence of Statin Users after Acute Ischemic Stroke
Chung, P., Yoon, B., Lee, Y., Shin, B., Kim, H. Y., Park, J. H., Kim, B., Yoo, B.-G., Shin, W.-C., Kim, E. G., et al. (2018) · European Neurology · doi:10.1159/000493530 · Cited by 36
Vogt, L., Bangalore, S., Fayyad, R. S., Melamed, S., Hovingh, G. K., DeMicco, D. A., & Waters, D. D. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010827 · Cited by 34
Williams, E. I., Betterton, R. D., Davis, T. P., & Ronaldson, P. T. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12020154 · Cited by 39
Rathor, M. Y., Rani, M. F. A., Jamalludin, A. R., Amran, M. Y., Shahrin, T. C. A., & Shah, A. (2012) · PubMed Central · Cited by 35
Yamawaki, M., Wada‐Isoe, K., Yamamoto, M., Nakashita, S., Uemura, Y., Takahashi, Y., Nakayama, T., & Nakashima, K. (2015) · Brain and Behavior · doi:10.1002/brb3.315 · Cited by 35
“Hyperlipidemia is a risk factor for vascular disorder (Tirschwell et al. 2004) and statin treatment has demonstrated benefits in stroke prevention and prognosis (Amarenco et al. 2006; Alvarez-Sabin et al. 2007).”
BackgroundPhase II Clinical Trial of Atorvastatin in Mild Traumatic Brain Injury
Robertson, C. S., McCarthy, J. J., Miller, E. R., Levin, H. S., McCauley, S. R., Swank, P. R., & Tr, F. T. M. C. M. T. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2016.4717 · Cited by 35
Uchiyama, S., Nakaya, N., Mizuno, K., Ohashi, Y., Tajima, N., Kushiro, T., Teramoto, T., & Nakamura, H. (2009) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2009.04.002 · Cited by 32
Siket, M. S., & Edlow, J. A. (2012) · Emergency Medicine Clinics of North America · doi:10.1016/j.emc.2012.05.001 · Cited by 32
Nanoshell assisted laser soldering of vascular tissue
Schöni, D., Bogni, S., Bregy, A., Wirth, A., Raabe, A., Vajtai, I., Pieles, U., Reinert, M., & Frenz, M. (2011) · Lasers in Surgery and Medicine · doi:10.1002/lsm.21140 · Cited by 32
Stauffer, M. E., Weisenfluh, L., & Morrison, A. (2013) · Vascular Health and Risk Management · doi:10.2147/vhrm.s52713 · Cited by 33
Hong, J., Sohn, S., Kwak, J.-H., Yoo, J., Chang, H. W., Kwon, O.-K., Jung, C., Chung, I., Bae, H., Lee, J. S., et al. (2017) · Stroke · doi:10.1161/strokeaha.117.016680 · Cited by 33
Causes and Secondary Prevention of Acute Ischemic Stroke in Adults
Jensen, M., & Thomalla, G. (2019) · Hämostaseologie · doi:10.1055/s-0039-1700502 · Cited by 43
Rost, N. S., & Etherton, M. R. (2020) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000000841 · Cited by 41
Prevention of recurrent ischemic stroke.
Dickerson, L. M., Carek, P. J., & Quattlebaum, R. G. (2007) · PubMed · Cited by 32
Conrad, M. F., Kang, J. L., Mukhopadhyay, S., Patel, V. I., LaMuraglia, G. M., & Cambria, R. P. (2013) · Annals of Surgery · doi:10.1097/sla.0b013e3182a5007b · Cited by 33
Secondary Prevention of Stroke in the Elderly: A Review of the Evidence
Alhusban, A., & Fagan, S. C. (2011) · The American Journal of Geriatric Pharmacotherapy · doi:10.1016/j.amjopharm.2011.04.002 · Cited by 32
Metadata
- Authors
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Affiliations
- Université Paris Diderot (FR)
- Corresponding author
- The Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-08-10
- Volume
- 355
- Issue
- 6
- Pages
- 549-559
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1546258268
- Cited by
- 2,887
- References
- 21
- Citations by year
- 2026: 86 · 2025: 96 · 2024: 119 · 2023: 112 · 2022: 135 · 2021: 134 · 2020: 139 · 2019: 140 · 2018: 129 · 2017: 132 · 2016: 139 · 2015: 125 · 2014: 142 · 2013: 160 · 2012: 149
- FWCI
- 200.93
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BOA (University of Milano-Bicocca) (submittedVersion)
- IRIS (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Funders
- Pfizer
- AstraZeneca
- GlaxoSmithKline
- Eisai
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cerebrovascular and Carotid Artery Diseases
- Keywords
- atorvastatin, high-intensity statin therapy, stroke, transient ischemic attack, secondary stroke prevention, LDL cholesterol lowering, hemorrhagic stroke, ischemic stroke, cardiovascular events, elevated liver enzymes, lipid-lowering therapy, mortality, serious adverse events
- MeSH terms
- Atorvastatin, Adult, Cardiovascular Diseases, Cerebral Hemorrhage, Cerebral Infarction, Ischemic Attack, Transient, Drug Therapy, Combination, Female, Heptanoic Acids, Humans, Cholesterol, LDL, Male, Pyrroles, Risk, Proportional Hazards Models, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.